期刊
STROKE
卷 38, 期 4, 页码 1393-1395出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/01.STR.0000260087.67462.80
关键词
clinical trials; outcome measures; stroke recovery
资金
- AHRQ HHS [1 R01 HS11392-01A1] Funding Source: Medline
- NINDS NIH HHS [1P50 NS051343] Funding Source: Medline
Clinical trials for acute stroke treatments have often used composite clinical rating scales as primary outcome measures of treatment efficacy. Recent preclinical and clinical studies highlight the opportunity to administer treatments in the subacute and chronic phase of stroke to promote neurological recovery. Because different neurological deficits recover to different extents at different rates after stroke, putative stroke recovery-promoting treatments may exert differential effects on various functional aspects of stroke recovery. For this reason, we propose that the use of modality-specific outcome measures may be best suited as primary end points in clinical trials of stroke recovery-promoting agents. The use of such end points may result in a more selective labeling of stroke recovery treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据